Listing 3 - Actual negotiations

Indication:

To decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive antineoplastic drug.

Indication:

Non-small cell lung cancer (NSCLC) expressing PD-L1 in ? 50% of tumour cells (Tumour Proportion Score [TPS] ? 50%), as determined by a validated test, with no EGFR, ALK or ROS1 aberrations, first-line treatment of adult patients who have locally advanced NSCLC who are not candidates for surgical resection or definitive chemoradiation, or metastatic NSCLC

Indication:

For the treatment of patients with locally advanced basal cell carcinoma (BCC) previously treated with a hedgehog pathway inhibitor

Indication:

Locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC), rearranged during transfection (RET) fusion-positive, in adult patients

Indication:

Atopic Dermatitis, Moderate to Severe

Indication:

Early breast cancer, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, at high risk of disease recurrence based on clinicopathological features and a Ki-67 score ?20%,for the adjuvant treatment of adult patients (in combination with endocrine therapy)

Indication:

Amyotrophic Lateral Sclerosis (ALS)

Indication:

Neovascular (wet) age-related macular degeneration (AMD), or visual impairment due to diabetic macular edema (DME), macular edema secondary to retinal vein occlusion (RVO), choroidal neovascularisation (CNV) secondary to pathologic myopia (PM), choroidal neovascularisation (CNV) secondary to ocular conditions other than AMD or PM, including but not limited to angioid streaks, post-inflammatory retinochoroidopathy, central serous chorioretinopathy or idiopathic chorioretinopathy

Indication:

Acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) in adult and pediatric patients 1 year or older who have developed hypersensitivity to E. coli-derived asparaginase.

Indication:

Acute Myeloid Leukemia (AML)